PoD-TPI: Probability-of-Decision Toxicity Probability Interval Design to Accelerate Phase I Trials
Author
Abstract
Suggested Citation
DOI: 10.1007/s12561-019-09264-0
Download full text from publisher
As the access to this document is restricted, you may want to search for a different version of it.
References listed on IDEAS
- Ruitao Lin, 2018. "Bayesian optimal interval design with multiple toxicity constraints," Biometrics, The International Biometric Society, vol. 74(4), pages 1320-1330, December.
- Suyu Liu & Ying Yuan, 2015. "Bayesian optimal interval designs for phase I clinical trials," Journal of the Royal Statistical Society Series C, Royal Statistical Society, vol. 64(3), pages 507-523, April.
- Ying Kuen Cheung & Rick Chappell, 2002. "A Simple Technique to Evaluate Model Sensitivity in the Continual Reassessment Method," Biometrics, The International Biometric Society, vol. 58(3), pages 671-674, September.
- Bryan M. Fellman & Ying Yuan, 2015. "Bayesian optimal interval design for phase I oncology clinical trials," Stata Journal, StataCorp LP, vol. 15(1), pages 110-120, March.
- Ying Kuen Cheung & Rick Chappell, 2000. "Sequential Designs for Phase I Clinical Trials with Late-Onset Toxicities," Biometrics, The International Biometric Society, vol. 56(4), pages 1177-1182, December.
Citations
Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
Cited by:
- Bo Huang & Naitee Ting, 2020. "Introduction to Special Issue on ‘Statistical Methods for Cancer Immunotherapy’," Statistics in Biosciences, Springer;International Chinese Statistical Association, vol. 12(2), pages 79-82, July.
Most related items
These are the items that most often cite the same works as this one and are cited by the same works as this one.- Thomas M. Braun, 2018. "Motivating sample sizes in adaptive Phase I trials via Bayesian posterior credible intervals," Biometrics, The International Biometric Society, vol. 74(3), pages 1065-1071, September.
- Qingyang Liu & Junxian Geng & Frank Fleischer & Qiqi Deng, 2022. "Efficacy-Driven Dose Finding with Toxicity Control in Phase I Oncology Studies," Statistics in Biosciences, Springer;International Chinese Statistical Association, vol. 14(3), pages 413-431, December.
- Yimei Li & Ying Yuan, 2020. "PA‐CRM: A continuous reassessment method for pediatric phase I oncology trials with concurrent adult trials," Biometrics, The International Biometric Society, vol. 76(4), pages 1364-1373, December.
- Anastasia Ivanova & Se Hee Kim, 2009. "Dose Finding for Continuous and Ordinal Outcomes with a Monotone Objective Function: A Unified Approach," Biometrics, The International Biometric Society, vol. 65(1), pages 307-315, March.
- Deborah Plana & Geoffrey Fell & Brian M. Alexander & Adam C. Palmer & Peter K. Sorger, 2022. "Cancer patient survival can be parametrized to improve trial precision and reveal time-dependent therapeutic effects," Nature Communications, Nature, vol. 13(1), pages 1-13, December.
- M. Clertant & J. O’Quigley, 2017. "Semiparametric dose finding methods," Journal of the Royal Statistical Society Series B, Royal Statistical Society, vol. 79(5), pages 1487-1508, November.
- Chen Li & Haitao Pan, 2020. "A phase I dose-finding design with incorporation of historical information and adaptive shrinking boundaries," PLOS ONE, Public Library of Science, vol. 15(8), pages 1-18, August.
- Erica Brittain & Dean Follmann & Song Yang, 2008. "Dynamic Comparison of Kaplan–Meier Proportions: Monitoring a Randomized Clinical Trial with a Long-Term Binary Endpoint," Biometrics, The International Biometric Society, vol. 64(1), pages 189-197, March.
- Yifei Zhang & Sha Cao & Chi Zhang & Ick Hoon Jin & Yong Zang, 2021. "A Bayesian adaptive phase I/II clinical trial design with late‐onset competing risk outcomes," Biometrics, The International Biometric Society, vol. 77(3), pages 796-808, September.
- Azriel, David, 2014. "Optimal sequential designs in phase I studies," Computational Statistics & Data Analysis, Elsevier, vol. 71(C), pages 288-297.
- Changying A. Liu & Thomas M. Braun, 2009. "Parametric non‐mixture cure models for schedule finding of therapeutic agents," Journal of the Royal Statistical Society Series C, Royal Statistical Society, vol. 58(2), pages 225-236, May.
- B. Nebiyou Bekele & Yisheng Li & Yuan Ji, 2010. "Risk-Group-Specific Dose Finding Based on an Average Toxicity Score," Biometrics, The International Biometric Society, vol. 66(2), pages 541-548, June.
- Nadine Houede & Peter F. Thall & Hoang Nguyen & Xavier Paoletti & Andrew Kramar, 2010. "Utility-Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Trials," Biometrics, The International Biometric Society, vol. 66(2), pages 532-540, June.
- Oron Assaf P. & Azriel David & Hoff Peter D., 2011. "Dose-Finding Designs: The Role of Convergence Properties," The International Journal of Biostatistics, De Gruyter, vol. 7(1), pages 1-17, October.
- Ying Kuen Cheung & Peter F. Thall, 2002. "Monitoring the Rates of Composite Events with Censored Data in Phase II Clinical Trials," Biometrics, The International Biometric Society, vol. 58(1), pages 89-97, March.
- Alessandra Giovagnoli, 2021. "The Bayesian Design of Adaptive Clinical Trials," IJERPH, MDPI, vol. 18(2), pages 1-15, January.
- Ying Kuen Cheung, 2002. "On the Use of Nonparametric Curves in Phase I Trials with Low Toxicity Tolerance," Biometrics, The International Biometric Society, vol. 58(1), pages 237-240, March.
- Sweeting, Michael & Mander, Adrian & Sabin, Tony, 2013. "bcrm: Bayesian Continual Reassessment Method Designs for Phase I Dose-Finding Trials," Journal of Statistical Software, Foundation for Open Access Statistics, vol. 54(i13).
- Yuan Ji & B. Nebiyou Bekele, 2009. "Adaptive Randomization for Multiarm Comparative Clinical Trials Based on Joint Efficacy/Toxicity Outcomes," Biometrics, The International Biometric Society, vol. 65(3), pages 876-884, September.
- Ying Yuan & Guosheng Yin, 2009. "Bayesian dose finding by jointly modelling toxicity and efficacy as time‐to‐event outcomes," Journal of the Royal Statistical Society Series C, Royal Statistical Society, vol. 58(5), pages 719-736, December.
More about this item
Keywords
Clinical trial design; Decision theory; Dose finding; Late-onset toxicity; Maximum tolerated dose;All these keywords.
Statistics
Access and download statisticsCorrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:stabio:v:12:y:2020:i:2:d:10.1007_s12561-019-09264-0. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .
Please note that corrections may take a couple of weeks to filter through the various RePEc services.